HHS Guidance Aims To Curb Overreporting Of Clinical-Trial Adverse Events
This article was originally published in The Gray Sheet
Executive Summary
A final HHS 1guidance explains that only a small subset of adverse events occurring in HHS-funded clinical research need be reported
You may also be interested in...
HHS Guidance To Clarify Which Adverse Events Researchers Need To Report
A final HHS guidance due in December will clarify which adverse events occurring in clinical trials must be reported to authorities
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.